Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 13, Issue 12, 2007, Pages 1545-1553

  Gasche, Christoph ^a,o   Berstad, Arnold ^b   Befrits, Ragnar ^c   Beglinger, Christoph ^d   Dignass, Axel ^e   Erichsen, Kari ^f   Gomollon, Fernando ^g   Hjortswang, Henrik ^h   Koutroubakis, Ioannis ⁱ   Kulnigg, Stefanie ^a   Oldenburg, Bas ^j   Rampton, David ^k   Schroeder, Oliver ^l   Stein, Jürgen ^l   Travis, Simon ^m   Van Assche, Gert ⁿ  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e AGAPLESION MARKUS KRANKENHAUS   (Germany)

^f HAUGESUND HOSPITAL   (Norway)

^g HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^h LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

ⁱ UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^k BARTS HEALTH NHS TRUST   (United Kingdom)

^l UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^m JOHN RADCLIFFE HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^o UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

Anemia; Ferritin; Guidelines; Inflammatory bowel diseases; Iron deficiency

Indexed keywords

AZATHIOPRINE; COSMOFER; CYANOCOBALAMIN; EPOMAX HEMAX; FERINJECT; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FOLIC ACID; HEMAX ERITRON; INJECTAFER; IRON; IRON DERIVATIVE; IRON DEXTRAN; MERCAPTOPURINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANEMIA; BLOOD TRANSFUSION; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC PROCEDURE; ENTERITIS; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; HYPERTENSION; IRON DEFICIENCY; IRON THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ANEMIA; BLOOD TRANSFUSION; FEMALE; HEMATINICS; HUMANS; INFLAMMATORY BOWEL DISEASES; IRON; MALE; VITAMINS;

EID: 38049048044     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20285     Document Type: Review

References (54)

1. Schreiber S, Wedel S. Diagnosis and treatment of anemia in inflammatory bowel disease. Inflamm Bowel Dis. 1997;3:204-216.
2. Gasche C. Complications of inflammatory bowel disease. Hepatogastroenterology. 2000;47:49-56.
3. Gasche C, Lomer MC, Cavill I, et al. Iron, anemia, and inflammatory bowel diseases. Gut. 2004;53:1190-1197.
4. Kulnigg S, Gasche C. Systematic review: managing anemia in Crohn's disease. Aliment Pharmacol Ther. 2006;24:1507-1523.
5. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):44S-49S.
6. Goddard AF, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anemia. British Society of Gastroenterology. Gut. 2000; 46(Suppl 3-4):IV1-IV5.
7. Pizzi LT, Weston CM, Goldfarb NI, et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:47-52.
8. Biancone L, Pavia M, Del Vecchio BG, et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis. 2001;7:287-294.
9. Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis. 2000;6:142-150.
10. Gasche C, Reinisch W, Lochs H, et al. Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci. 1994;39:1930-1934.
11. Horina JH, Petritsch W, Schmid CR, et al. Treatment of anemia in inflammatory bowel disease with recombinant human erythropoietin: results in three patients. Gastroenterology. 1993;104:1828-1831.
12. Lomer MC, Kodjabashia K, Hutchinson C, et al. Intake of dietary iron is low in patients with Crohn's disease: a case-control study. Br J Nutr. 2004;91:141-148.
13. Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006;12:1101-1106.
14. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.
15. Eccles M, Clapp Z, Grimshaw J, et al. North of England evidence based guidelines development project: methods of guideline development. BMJ. 1996;312:760-762.
16. Perry GS, Byers T, Yip R, et al. Iron nutrition does not account for the hemoglobin differences between blacks and whites. J Nutr. 1992;122:1417-1424.
17. WHO, UNICEF, UNU. Iron Deficiency Anemia: Assessment, Prevention and Control. Report of a joint WHO/UNICEF/UNU consultation. Geneva: World Health Organization; 1998.
18. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55(Suppl 1):i1-15.
19. Rath HC, Caesar I, Roth M, et al. [Nutritional deficiencies and complications in chronic inflammatory bowel diseases]. Med Klin. 1998;93:6-10.
20. Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition. 2006;22:1210-1213.
21. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta. 2003;329:9-22.
22. Hansen TM, Hansen NE, Birgens HS, et al. Serum ferritin and the assessment of iron deficiency in rheumatoid arthritis. Scand J Rheumatol. 1983;12:353-359.
23. Bartels U, Pedersen NS, Jarnum S. Iron absorption and serum ferritin in chronic inflammatory bowel disease. Scand J Gastroenterol. 1978;13:649-656.
24. Ali M, Rigolosi R, Fayemi AO, et al. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet. 1982;1:652-655.
25. Bruner AB, Joffe A, Duggan AK, et al. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet. 1996;348:992-996.
26. Chavarro JE, Rich-Edwards JW, Rosner BA, et al. Iron intake and risk of ovulatory infertility. Obstet Gynecol. 2006;108:1145-1152.
27. Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123-130.
28. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med. 1997;126:782-787.
29. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100:2503-2509.
30. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol. 2005;40:1058-1065.
31. Erichsen K, Hausken T, Ulvik RJ, et al. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol. 2003;38:543-548.
32. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med. 1996;334:619-623.
33. Gasche C, Dejaco C, Reinisch W, et al. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion. 1999;60:262-267.
34. Gasche C, Waldhoer T, Feichtenschlager T, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 2001;96:2382-2387.
35. Devalia V. Diagnosing vitamin B-12 deficiency on the basis of serum B-12 assay. BMJ. 2006;333:385-386.
36. Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2001;7:250-255.
37. Kulnigg S, Rumyantsev V, Stoinov S, et al. A novel intravenous iron formulation for treatment of anemia in IBD: the Ferinject randomized, controlled trial. Gastroenterology. 2007;132(Suppl 1):A501.
38. Seril DN, Liao J, West AB, et al. High-iron diet: foe or feat in ulcerative colitis and ulcerative colitis-associated carcinogenesis. J Clin Gastroenterol. 2006;40:391-397.
39. Lee KM, Sartor RB. Oral iron potentiates immune-mediated colitis in IL-10 deficient mice. Gastroenterology. 2007;132:A701.
40. De Silva AD, Tsironi E, Feakins RM, et al. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther. 2005;22:1097-1105.
41. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anemia. Lancet. 2007;369:1502-1504.
42. Ganzoni AM. [Intravenous iron-dextran: therapeutic and experimental possibilities]. Schweiz Med Wochenschr. 1970;100:301-303.
43. Shaffer JL, Higham C, Turnberg LA. Hazards of slow-release preparations in patients with bowel strictures. Lancet. 1980;2:487.-
44. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118:1142-1147.
45. Zlotkin S, Arthur P, Antwi KY, et al. Randomized, controlled trial of single versus 3-times-daily ferrous sulfate drops for treatment of anemia. Pediatrics. 2001;108:613-616.
46. Dohil R, Hassall E, Wadsworth LD, et al. Recombinant human erythropoietin for treatment of anemia of chronic disease in children with Crohn's disease. J Pediatr. 1998;132:155-159.
47. Koutroubakis IE, Karmiris K, Makreas S, et al. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anemia: a pilot study. Eur J Gastroenterol Hepatol. 2006;18:421-425.
48. Derijks LJ, Gilissen LP, Hooymans PM, et al. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:715-729.
49. Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187-208.
50. Decaux G, Prospert F, Horsmans Y, et al. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med. 2000;135:256-262.
51. Jobson B, Garza A, Sninsky CA. Red cell mean corpuscular volume (MCV) correlates with 6 thioguanine nucleotide (6TG) levels during azathioprine or 6-MP therapy for Crohn's disease. Gastroenterology. 2001;120:A4.
52. Crichton RR, Danielson BG, Geisser P. Iron therapy with special emphasis on intravenous administration. Bremen: UNI-MED; 2005.
53. Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378-382.
54. Seid MH, Mangione A, Valaoras TG, et al. Safety profile of iron carboxymaltose, a new high dose intravenous iron in patients with iron deficiency anemia. Blood. 2006;108:8B.